NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics Inc (NASDAQ:MGNX) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.03. The biopharmaceutical company had revenue of $18.74 million for the quarter, compared to analysts' expectations of $23.33 million. MacroGenics had a negative net margin of 303.08% and a negative return on equity of 59.67%. View MacroGenics' Earnings History.

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MacroGenics.

MacroGenics will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 analysts have issued 1 year price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' share price to reach $22.00 in the next year. This suggests a possible upside of 91.3% from the stock's current price. View Analyst Price Targets for MacroGenics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.

Media headlines about MGNX stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MacroGenics earned a news impact score of 0.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for MacroGenics.

MacroGenics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,180,000 shares, an increase of 14.5% from the January 15th total of 3,650,000 shares. Based on an average daily volume of 575,700 shares, the days-to-cover ratio is currently 7.3 days. Approximately 9.5% of the company's stock are short sold. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Eidos Therapeutics (EIDX), Cambrex (CBM), Xencor (XNCR), PPD (SDGR), Esperion Therapeutics (ESPR), Forty Seven (FTSV), Heron Therapeutics (HRTX), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD), Tricida (TCDA), Ligand Pharmaceuticals (LGND), Aimmune Therapeutics (AIMT), Arvinas (ARVN), Akcea Therapeutics (AKCA) and Alder Biopharmaceuticals (ALDR).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Incyte (INCY), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

MacroGenics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.94%), Sofinnova Investments Inc. (2.40%), Rhenman & Partners Asset Management AB (2.17%), Pinnacle Associates Ltd. (1.75%), FMR LLC (1.70%) and Candriam Luxembourg S.C.A. (1.53%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Jefferies Group LLC, Spark Investment Management LLC, Massachusetts Financial Services Co. MA, Citigroup Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for MacroGenics.

MGNX stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Panagora Asset Management Inc., Oxford Asset Management LLP, Geode Capital Management LLC, Principal Financial Group Inc. and Amia Capital LLP. View Insider Buying and Selling for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $11.50.

MacroGenics has a market capitalization of $563.02 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.

The official website for MacroGenics is http://www.macrogenics.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.